Novogen Limited (KZIA) – What Are Analysts Saying About This Stock?

Shares of Novogen Limited (NASDAQ:KZIA) have been assigned an average rating of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $29.50.

A number of equities research analysts recently weighed in on the company. Canaccord Genuity Group assumed coverage on Novogen in a research note on Thursday, August 13th. They issued a “buy” rating and a $29.00 price target on the stock. BTIG Research reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Novogen in a report on Thursday, September 10th. Needham & Company LLC assumed coverage on shares of Novogen in a research report on Friday, October 30th. They issued a “buy” rating and a $27.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Novogen in a report on Thursday, October 15th. Finally, Guggenheim began coverage on Novogen in a research report on Wednesday, October 21st. They set a “buy” rating and a $35.00 price objective for the company.

Novogen Stock Up 2.6%

KZIA opened at $7.18 on Friday. Novogen has a 12-month low of $4.86 and a 12-month high of $17.40. The business has a 50 day moving average of $9.56 and a 200-day moving average of $10.50.

Novogen Company Profile

Novogen Limited was an Australian biotechnology company that developed novel therapies for cancer. The company focused on small-molecule drug candidates designed to target biological pathways involved in tumor growth and survival, with an emphasis on cancers that have limited treatment options.

In 2016, Novogen changed its name to Kazia Therapeutics Limited and continued its oncology research under the Kazia name. Its principal development program became paxalisib, an investigational PI3K/mTOR inhibitor being studied for brain cancers, including glioblastoma and brain metastases.